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Purpose: To assess the association of gender, cigarette smoking, body-mass index, and nine genetic risk variants with
cuticular drusen (CD), a well recognized subtype of age-related macular degeneration (AMD).
Methods: A total of 757 patients with AMD, including 217 patients with CD, and 553 control individuals were
interviewed with a questionnaire and underwent an ophthalmic examination. Venous blood samples were obtained for
genomic DNA extraction, and genotyping was performed of single nucleotide polymorphisms previously associated
with AMD. Odds ratios were calculated for patients with CD, using unaffected control individuals as a reference.
Furthermore, odds ratios in patients with CD were compared to those in patients with “non-CD” AMD.
Results: The CD subtype of AMD was significantly associated with current smoking as well as variants in the
complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), complement factor B/complement
component 2 (CFB/C2), complement component 3 (C3), and apolipoprotein E (APOE) genes. In patients with CD, the
association with the CFH Y402H risk allele was significantly higher (p=0.022), whereas the association with current
smoking was significantly lower (p<0.001) than in the heterogeneous group of patients with “non-CD” AMD.
Conclusions: The AMD subtype of CD was associated with previously identified genetic AMD risk factors. However,
the association with the CFH Y402H risk allele appeared to be stronger, whereas the association with smoking was less
pronounced when compared to AMD as a whole. This study suggests a more important role for genetic factors than
environmental factors in the development of this well defined subtype of AMD. These findings stress the importance of
detailed phenotyping in AMD to identify homogeneous AMD subtypes, which may be associated with different risk
factors and disease mechanisms. Such studies will improve the accuracy of predictive models and the effectiveness of
preventive and therapeutic options in AMD.
Age-related macular degeneration (AMD) is the most
common cause of irreversible and progressive visual loss
among the elderly in the Western world [1,2]. The
abnormalities of this disorder range from discrete drusen
deposits and pigmentary changes in early AMD to
geographic atrophy and/or choroidal neovascularization
(CNV) in the advanced forms.
AMD is a clear example of a multifactorial disease, and
a wide variety of risk factors have been associated with the
development and progression of AMD. Advanced age,
female gender, cigarette smoking, and a high body-mass
index (BMI >30) have been reported as the most
consistently reproducible demographic and environmental
risk factors in AMD [3-7]. Familial aggregation analyses
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and twin studies have provided clear evidence of
heritability, and more recently strong associations were
found with the Y402H (rs1061170) polymorphism in the
complement factor H (CFH) gene and with the A69S
(rs10490924) polymorphism in the age-related maculopathy
susceptibility 2 (ARMS2) gene [8-12]. These two allelic
variants contribute to late AMD in more than 80% of cases
[13,14]. Other genes that harbor established risk variants for
AMD include the complement factor B (CFB), complement
component 2 (C2), complement component 3 (C3),
complement factor I (CFI), and the apolipoprotein E
(APOE) genes [15-22].
The fact that AMD is highly heterogeneous in its
clinical presentation is well recognized. Nevertheless, most
studies reporting on the influence of environmental and
genetic risk factors analyzed the AMD phenotype as a
whole, without attempting to determine these risk factors in
more homogeneous subtypes of the disorder. Based on the
clinically observed abnormalities, several subtypes of AMD
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may be recognized, including polypoidal choroidal
vasculopathy, retinal angiomatous proliferation, and
cuticular drusen (CD) [23-29]. The latter, formerly known
as basal laminar drusen [30], is characterized by the
fundoscopic findings of innumerable, small (25 µm to
75 µm), uniformly sized, round drusen [31]. Most
commonly appearing in early adulthood, these drusen are
easy visualized with fluorescein angiography (FA). In more
advanced stages, the multitude of drusen produce a typical
“stars-in-the-sky” appearance in early phases of the
angiogram [32]. Researchers have estimated that the CD
phenotype comprises approximately 10% of the AMD
spectrum [29].
In the present study, we investigated whether the AMD
subtype of CD displays different environmental and genetic
risk factors than AMD as a whole.
METHODS
Subjects: In this study, we evaluated a total of 757 unrelated
patients with AMD, including 217 patients with CD, and
553 control individuals. All subjects were retrieved from the
European Genetic Database (EUGENDA), a multicenter
database for clinical and molecular analysis of AMD. In the
current study, only Caucasian participants from the
Nijmegen (the Netherlands) area participated.
Before being enrolled in EUGENDA, all subjects were
interviewed with a questionnaire to document their medical
history and lifestyle habits, such as BMI and smoking
status. Subjects who reported a kidney disease were
excluded from the study to preclude including patients with
membranoproliferative glomerulonephritis (MPGN) type II.
Pupillary dilatation was achieved with topical 1.0%
tropicamide and 2.5% phenylephrine before retinal imaging.
Digital non-stereoscopic 30° color fundus photography was
performed with a Topcon TRC 50IX (Topcon Corporation,
Tokyo, Japan). In addition, patients with AMD received FA
and high-resolution Fourier-domain optical coherence
tomography (FD-OCT), performed with a combined
confocal scanning laser ophthalmoscope/FD-OCT device
(SPECTRALIS, Heidelberg Engineering, Heidelberg,
Germany).
Color fundus photographs of both eyes of all cases were
evaluated by two independent reading center graders
according to the standard protocol of the Cologne Image
Reading Center and Laboratory (CIRCL). AMD was
defined by using international standards as described
previously [33]. Individuals of similar age as the AMD
cases and who exhibited no signs of AMD in either eye
were collected as controls. The CD subtype was defined as a
symmetric distributed pattern between both eyes of at least
50 scattered, uniformly-sized, small (25 µm to 75 µm)
hyperfluorescent drusen on FA in each eye, of which a
minimum of 20 drusen are located outside the Wisconsin
age-related maculopathy grading template [34]. After the
grading was completed, the AMD cohort was divided into a
cohort of patients with the AMD subtype of CD and a group
of patients with “non-CD” AMD.
This study was reviewed and approved by the local
institutional review boards and adhered to the tenets of the
Declaration of Helsinki. Written informed consent was
obtained from all individuals before they participated in the
study.
Single nucleotide polymorphism genotyping: Genomic DNA
was isolated from peripheral blood leukocytes using
standard techniques and stored at −20 °C. Genotyping of
single nucleotide polymorphisms (SNPs) in the CFH
(rs1410996), ARMS2 (rs10490924), CFB (rs4151667), C2
(rs9332739), C3 (rs2230199), CFI (rs10033900), and APOE
(E2 allele; rs7412 and E4 allele; rs429358) genes in the
“non-CD” AMD, CD, and control cohorts were performed
as previously described [35]. The CFH variant Y402H
(rs1061170) was analyzed with direct sequencing of PCR
products using forward primer 5′-TCA TTG TTA TGG
TCC TTA GG-3′ and reverse primer 5′-AAA GAC ATG
AAC ATG CTA GG-3′. These nine SNPs were selected
because they were previously associated with AMD
[8-12,15-22]. Fourteen percent of the genotypes were done
in duplicate, resulting in a concordance of ≥99.9%.
Statistics: Genotype frequencies in the control individuals
were tested for Hardy–Weinberg equilibrium. Baseline and
clinical characteristics were analyzed with standard
descriptive statistics, and differences in gender, smoking
status, and BMI were analyzed with a multivariate logistic
regression analysis to adjust for the covariates age, gender,
BMI, and smoking status where applicable. Subsequently, to
study the associations of allele frequencies for AMD-
associated SNPs among the “non-CD” AMD cohort, the CD
cohort, and the controls, a multivariate logistic regression
analysis was performed to adjust for the covariates age,
gender, smoking status, and BMI. The differences between
the three cohorts are presented as odds ratios (ORs) with
95% confidence intervals (95% CIs).
Data analysis was performed using SPSS software,
version 18.0 (SPSS Inc., Chicago, IL). The reported p
values are two-sided, and a value of < 0.05 was considered
statistically significant.
RESULTS
Baseline demographics and risk allele frequencies of the
“non-CD” AMD (n=540), CD (n=217), and control (n=553)
cohorts are depicted in Table 1 and Table 2. The mean age
was 76.7 years (range 55–94; standard deviation [SD] 7.4)
in the “non-CD” AMD cohort, 69.3 years (range 50–91; SD
10.4) in the CD cohort, and 73.1 years (range 55–92; SD
6.3) in the controls.
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Current smoking showed an association with CD
(p=0.032; OR: 2.06; 95% CI: 1.07–4.00), and this
association was significantly lower (p<0.001; OR: 0.32;
95% CI: 0.17–0.58) compared to the “non-CD” AMD
cohort. Female gender showed a trend (p=0.086), and no
association with BMI was found for CD.
All genotype frequencies conformed to Hardy–
Weinberg equilibrium in the control cohort. The risk allele
frequency of the CFH Y402H (rs1061170) variant was
64.1% in the CD cohort, which closely approximates the
prevalence reported previously in patients extensively
affected with CD [25]. A significantly higher CFH Y402H
risk allele frequency was found in the CD cohort when
compared with the control cohort (p<0.001; OR: 2.88; 95%
CI: 2.23–3.73), and when compared to the “non-CD” AMD
cohort (p=0.022; OR: 1.35; 95% CI: 1.04–1.74).
The risk allele frequencies of the ARMS2 (rs10490924),
CFH (rs1410996), C3 (rs2230199), and APOE E2 (rs7412)
variants were significantly higher in the CD cohort
compared to the control cohort, and the protective allele
frequencies of the C2 (rs9332739), CFB (rs4151667), and
APOE E4 (rs429358) variants were significantly lower in
the CD cohort compared to the control cohort. These odds
ratios were comparable with the “non-CD” AMD cohort,
and no significant differences were observed between the
CD and “non-CD” AMD cohort for these SNPs. No
association with the CFI (rs10033900) risk allele was found
in the CD cohort.
DISCUSSION
The clinical spectrum of AMD is broad, and this clinical
heterogeneity will influence the results of association
studies on demographic, environmental, and genetic risk
factors. Improved phenotyping will increase the power of
association studies in predictive models for AMD [36,37],
and will lead to a better understanding of the pathogenesis
of the different AMD subtypes.
In the present study, we focused on CD, a well defined
subtype of AMD. The relatively early onset of CD, as well
as the observation that the CD phenotype is often clustered
in families, implies a greater contribution of the genetic
constitution when compared to AMD in general [23,25,29].
This is further supported by our observation that one of the
most important environmental risk factors, current smoking,
showed a significantly lower association with CD than with
“non-CD” AMD. The latter may also imply that the general
advice to patients with AMD for cessation of smoking could
be of limited effect in individuals with the CD subtype of
AMD. However, this does certainly not mean that cessation
of smoking should not be encouraged in patients with CD as
current smoking could worsen the natural history of the
disease.
Genetic evaluation of our CD cohort showed significant
associations between this AMD subtype and variants in the
CFH, ARMS2, CFB, C2, C3, and APOE genes. Risk alleles
of the rs1410996 (CFH), rs10490924 (ARMS2), rs4151667
(CFB), rs9332739 (C2), rs2230199 (C3), rs7412 (APOE
E2), and rs429358 (APOE E4) SNPs were significantly
associated with CD. However, no significant differences for
the previously mentioned risk alleles were observed
between patients with CD and AMD in general. This
suggests that there is a shared genetic background between
AMD in general and CD, which has also been described for
other AMD subtypes such as polypoidal choroidal
vasculopathy and retinal angiomatous proliferation
[24,26,28,38]. A lack of association between the
rs10033900 (CFI) risk allele and CD could be due to
insufficient power in our study to detect small effects.
However, the debate over whether this variant is associated
with AMD continues as conflicting results have been
observed [16,17,39]. Additional studies are needed to clarify
the nature of the association between AMD and this
particular variant near the CFI gene.
A previous study of Caucasian patients who were
severely affected with CD demonstrated a strong association
with the Y402H (rs1061170) variant in the CFH gene [25].
Our study shows that, in spite of the various stages of the
CD phenotype included in our cohort, patients with CD are
1.35 times more likely to carry the CFH Y402H risk allele
compared to patients with “non-CD” AMD. This higher
allele frequency of the CFH Y402H risk allele in patients
with CD suggests that activation of the alternative pathway
of the complement system may play a larger role in the
pathogenesis of the CD phenotype than in the remainder of
the AMD phenotypes [40,41]. This is supported by our
previous studies that identified rare pathogenic CFH
mutations in a subset of families with CD [23,29]. These
mutations have not been found in patients with AMD who
did not display the CD phenotype. In patients with MPGN
type II, or dense deposit disease, CFH mutations and
disturbed serum complement activation levels have also
been demonstrated [42]. Remarkably, almost 70% of
individuals with MPGN type II develop extensive drusen in
a pattern matching that of extensive CD during their second
decade of life [43]. In approximately 10% of these patients,
CNV and/or central geographic atrophy may develop at a
relatively young age [44-46]. These alterations of the
complement system may contribute to the relatively early
onset of CD.
The increased insights into the mechanisms underlying
AMD have led to possible therapeutic options that have
recently entered phase 1 clinical trials [47]. One option may
be the use of specific anti-inflammatory molecules that
block complement activation [47]. These complement
inhibitors may especially benefit individuals with the CD
subtype of AMD, where complement activation appears
more fundamental to the disease process compared to AMD
in general.
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In conclusion, the analysis of a large cohort of the CD
subtype of AMD has revealed that genetic risk factors
affecting the complement system are especially prevalent in
these patients. In addition, the environmental risk factor of
smoking appears less influential than in AMD in general.
These findings stress the importance of detailed
phenotyping in AMD to identify homogeneous AMD
subgroups, which may be associated with different risk
factors and disease mechanisms. Such studies may improve
the accuracy of predictive models and the effectiveness of
preventive and therapeutic options in AMD.
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